A phase Ib clinical trial in HER2– breast cancer patients identified a four-gene signature (FBXW2, CCND2, CTBP2, and WIF1) as a potential predictive biomarker for the response to combined treatment with paclitaxel and vantictumab (Zhang et al., 2018). This evidence concerns the gene WIF1 and breast carcinoma.